Avid Bioservices Inc (CDMO)

[md1225]

Great analysis MH I am currently doing a market analysis to finish my article I originally aimed lower 4-6 Billion value upon first approval "within next 6 months" with pie in the sky hitting 40 Billion to 60 Billion if Bavituximab instills immunity and CRs.

In all reality I envision a buyout to the tune of 20 Billion this time next year if trial halted by March 2016. Then Bristol Myers can make Bavituximab SOC for all cancers added to an ever changing immunotherapy, chemotherapy, radiation and surgery assault.